Are you above the legal age to view this content in your province/state?

Home / Industry News / NHS to fast-track supply of cannabis-based epilepsy treatment

NHS to fast-track supply of cannabis-based epilepsy treatment

NHS to fast-track supply of cannabis-based epilepsy treatment

London, December 21, 2109 (INDEPENDET)- Thousands of people with severe epilepsy will be able to access a cannabis-based treatment on the NHS from the new year, it has been revealed.

Epidyolex, a cannabidiol (CBD) oral medication, has been fast-tracked by the health service in England to be available from 6 January.

Hundreds of children will be among around 2,000 people across the country who it is estimated will benefit from the change in policy.

The drug was recommended for use to treat two rare types of epilepsy – Lennox-Gastaut and Dravet syndromes – back in November.

Clinical trials showed the drug could reduce the number of seizures by up to 40 per cent in some patients.

A change in the law in 2018 had already made it legal for doctors to prescribe medicinal but many have been reluctant to do so, citing a lack of clear guidance on the issue.

Campaign group End Our Pain welcomed the new move and said the announcement would be a boost to families, some of who are currently paying up to £2,000 a month privately for such products.

Millie Hinton, director, said: “They have been pushed to financial breaking point funding the only medicine that gives their children significant seizure control and the quality of life they deserve. Some have actually felt forced to sell their family homes.”

But she added that the NHS should now go further by also providing medication containing Tetrahydrocannabinol (THC) for those with different forms of epilepsy.

“While fast-tracking access to a CBD-only product is a step in the right direction for some desperate families, for those that need the products containing both CBD and THC it’s another false dawn and missed opportunity,” she said. “These families need immediate action to secure NHS prescriptions for the CBD and THC whole plant medical cannabis products.

Independent news email

Only the best news in your inboxContinue

Register with your social account or click here to log inwould like to receive morning headlinesMonday – Friday plus breaking news alerts by email

“It is unbelievably cruel to leave these vulnerable families in such a desperate state.”

Simon Stevens, NHS chief executive, said the service was “committed, through the long term plan, to improving the lives of all those affected by rare diseases.”

He added: “Living with or caring for someone with severe epilepsy is exceptionally challenging, especially as there are so few treatments available for the rare forms of the condition.

“Thousands of people including children will now have access to this treatment, which has the potential to make a real difference.”

Disclaimer

Investment Value Finders specializes in providing opinions and information on stocks to individuals who wish to receive them. Our reports are construed for information purposes solely and are distributed free of charge to individuals who wish to receive them.


Investment Value Finders does not promote, condone or advocate licit or illicit drug use. Investment Value Finders cannot be held responsible for materials or contests posted on its website pages, or pages to which we provide links, which promote, condone or advocate licit or illicit drug use or illegal activities.


DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser. We are neither licensed nor qualified to provide investment advice.


Investment Value Finders occasionally receives direct compensation for hosting links (or other* advertisements) to third party content that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where the link text contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.


Investment Value Finders is intended for those 21+ years of age only!

Check Also

Isolate, Distillate, Full Spectrum: Understanding What CBD You're Buying

Isolate, Distillate, Full Spectrum: Understanding What CBD You’re Buying

This story originally appeared on Leaf Report There’s no question cannabidiol (CBD) products are flying off …